Insider Selling: IQVIA (NYSE:IQV) Insider Sells 5,500 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

IQVIA Stock Down 2.2%

NYSE:IQV traded down $5.18 during trading hours on Tuesday, reaching $228.18. The company had a trading volume of 1,471,738 shares, compared to its average volume of 1,812,230. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $37.56 billion, a price-to-earnings ratio of 28.31, a P/E/G ratio of 1.99 and a beta of 1.18. The business’s 50-day simple moving average is $196.05 and its two-hundred day simple moving average is $186.76.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.61 earnings per share for the current year.

IQVIA declared that its board has authorized a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Royal Bank Of Canada boosted their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $241.88.

Hedge Funds Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Franklin Street Advisors Inc. NC bought a new position in IQVIA in the 4th quarter worth $15,724,000. CWM LLC increased its position in IQVIA by 23.9% in the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after buying an additional 10,762 shares in the last quarter. Calamos Advisors LLC raised its stake in shares of IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after buying an additional 137,441 shares during the period. Assetmark Inc. lifted its position in shares of IQVIA by 33.6% during the 4th quarter. Assetmark Inc. now owns 172,625 shares of the medical research company’s stock valued at $38,911,000 after buying an additional 43,436 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of IQVIA by 68.2% during the 4th quarter. KBC Group NV now owns 779,128 shares of the medical research company’s stock valued at $175,624,000 after buying an additional 315,883 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.